Avenoir Cosmetics Launches Cell Repair Serum – Clinical Strength to Enhance Skin Tone & Minimize Appearance of Sunspots, Blemishes, Discoloration,…
By daniellenierenberg
TipRanks
Investing is all about profits, and part of generating profits is knowing when to start the game. The old adage says to buy low and sell high, and while its tempting just to discount cliches like that, theyve passed into common currency because they embody a fundamental truth. Buying low is always a good start in building a portfolio.The trick, however, is recognizing the right stocks to buy low. Prices fall for a reason, and sometimes that reason is fundamental unsoundness. Fortunately, Wall Streets analysts are busy separating the wheat from the chaff among the markets low-priced stocks, and some top stock experts have tagged several equities for big gains. These stocks are trading low now but the reasons are not necessarily bad for investors.Weve used the TipRanks database to pull up the data and reviews on two stocks that are priced low now, but may be primed for gains. Theyve been getting positive reviews, and despite their share depreciation, they hold Buy ratings and show upwards of 60% upside potential.Digital Media Solutions (DMS)We will start with Digital Media Solutions, an adtech company which connects online advertisers with customers through performance-based branding and marketplace solutions. DMS boasts a powerful consumer intelligence database, which it uses to fine-tune customer acquisition campaigns while offering advertisers accountability for the project budget.DMS went public in July of this year, via a merger with a special purpose acquisition company, Leo Holdings. The combination took the DMS name for the ticker, and initiated trading at $10 per share. The stock has been volatile since, and is currently down 27% since it started trading.Digital advertising is a huge and growing sector, worth $100 billion in 2019 and expected to reach $130 billion by the end of next year. DMS has a solid piece of that cash cow, and the Q3 numbers demonstrate that. Quarterly revenue hit a company record, of $82.8 million, which was up 10% sequentially and 44% year-over-year. Of that total revenue, the company saw a gross profit of $25.1 million, for a 30% gross margin. All in all, DMSs first quarter as a publicly traded company showed strong results.Covering the stock for Canaccord is analyst Maria Ripps, who is rated 5 stars by TipRanks, and stands in the top 1% out of more than 7,100 stock analysts. The company saw meaningful volume growth from both new and existing clients, with particular strength from its auto insurance business along with the eCommerce, education, and non-profit verticals We continue to think investors will gradually come to appreciate DMS similarities with other leading digital marketing peers that trade at more premium valuations, and expect multiple expansion over time as the story becomes better understood, Ripps noted.To this end, Ripps rates DMS stock a Buy, and her $15 price target suggests an upside of 106% from the current share price of $7.20. (To watch Ripps track record, click here)Overall, DMS Moderate Buy consensus rating is based on 2 recent reviews, both positive. The stock has an average price target of $14, which indicates a 92% upside potential. (See DMS stock analysis on TipRanks)ViaSat, Inc. (VSAT)From digital advertising we move on to digital networking. ViaSat provides customers with high-speed broadband access through a secure satellite network system. The company serves both military and commercial markets, meeting the growing need for secure communications links.The anti-coronavirus shutdown policies have particularly hard on ViaSat. This may sound counterintuitive, as online networking has been busier than ever, but a large segment of ViaSats business comes from the airlines, and with air travel first grounded and still facing depressed travel volumes, ViaSats shares have yet to recover from their February/March swoon.On a positive note and one that is indicative of the essential nature of secure satellite communications in todays networked economy ViaSat reported $577 million in Q3 contract awards, representing a 29% yoy gain. For the year to date, the company has seen awards totaling $1.9 billion, which is up 5% from this time last year. The third quarter (the companys fiscal Q2) revenues and earnings were somewhat mixed, reflecting both the increase in contract awards and the decline in airline business. Revenues were $554 million, down 6% yoy, but up almost 4% sequentially. EPS was 3 cents per share, beating the predicted 5 cent loss by a wide margin.JPMorgan analyst Philip Cusick writes of ViaSat: [We] believe long-term growth levers remain intact highlighted by record segment backlog of $1.1b We view ViaSat as a satellite innovation leader and believe the companys future ViaSat-3 fleet will accelerate growth in satellite services over the coming years. At the same time, we see a long-term government systems tailwind driven by the companys radio portfolio, mobile broadband, and SATCOM.In line with his bullish comments, Cusick rates VSAT shares an Overweight (i.e. Buy), and his $60 price target implies ~72% upside on the one-year time horizon. (To watch Cusicks track record, click here)Overall, the stock has 5 recent reviews, including 3 Buys and 2 Holds. Shares are priced at $34.14, and the average price target of $55 suggests a 61% upside potential from that level. (See VSAT stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
- Tissue regeneration: Reserve or reverse? - Science Magazine - February 19th, 2021
- Heres why natural ingredients and science-backed formulations are the perfect combination - Vogue India - February 19th, 2021
- The ultimate path to skin rejuvenation - Philstar.com - February 19th, 2021
- Trupure Organics Is First 50-Plus Brand Devoted to That Market's Distinct Needs - PRNewswire - February 19th, 2021
- Mouth Sores from Chemo: Symptoms, Causes, and Treatments - Healthline - February 19th, 2021
- Research Associate in Stem Cells and Regenerative Medicine job with KINGS COLLEGE LONDON | 246711 - Times Higher Education (THE) - February 17th, 2021
- Gergis Explains the Differences Between Acute and Chronic GVHD - Targeted Oncology - February 17th, 2021
- Smart Stem Cells Made From Fat Have the Power to Heal - Freethink - February 14th, 2021
- Manageable Safety Profile Observed in Phase 1 Studies Examining UCART19 for Pediatric and Adult Patients with B-Cell ALL - Cancer Network - February 11th, 2021
- Platelet Rich Plasma Therapy: The answer to a rejuvenated body, skin, hair and sex life! - Longevity LIVE - Longevity LIVE - February 11th, 2021
- Paragon Biosciences Expands Cell And Gene Therapy Platform - Contract Pharma - February 10th, 2021
- [Full text] Successful Use of Nivolumab in a Patient with Head and Neck Cancer Aft | OTT - Dove Medical Press - February 10th, 2021
- Two Studies Shed Light on How and Where the Body Can Add New Fat Cells - Technology Networks - February 4th, 2021
- Heidi Klum loves to pamper her skin with goodies from Drunk Elephant and Glossier - woman&home - February 4th, 2021
- I Tried MAC's Virtual Try-On Tool & Here's What Happened - GLAMOUR UK - February 4th, 2021
- When to take fish oil: Timing, dosages and side effects - Medical News Today - February 4th, 2021
- World Cancer Day 2021: What are Blood Cancers, Types, Symptoms, Treatment and data in India? - Jagran Josh - February 4th, 2021
- Heidi Klum loves to pamper her skin with goodies from Drunk Elephant and Glossier - Woman & Home - February 3rd, 2021
- Paragon Biosciences Launches CiRC Biosciences to Expand Cell and Gene Therapy Platform - PRNewswire - February 3rd, 2021
- The 32 Best Beauty Products That Launched in January - Coveteur - January 31st, 2021
- Unboxing: the Best Beauty Items We Tried in January - Prestige Online - January 31st, 2021
- ToolGen ties up with 3D bioprinting company to apply induced pluripotent stem cells to gene correction - Aju Business Daily - January 29th, 2021
- Researchers use patients' cells to test gene therapy for rare eye disease - National Institutes of Health - January 29th, 2021
- Opdivo Side Effects: What They Are and How to Manage Them - Healthline - January 29th, 2021
- Protein identified that may help treat Parkinsons disease - Medical News Today - January 29th, 2021
- Why Hair Goes Gray, and How to Cover It If You Want To - NewBeauty Magazine - January 29th, 2021
- Valentina Greco Receives the 2021 ISSCR Momentum Award < Yale School of Medicine - Yale School of Medicine - January 27th, 2021
- Essent Biologics Launches With A Mission To Provide Human-Derived Biomaterials And 3D Biology Data For Cell Therapy And Tissue Engineering - The Grand... - January 27th, 2021
- How to Treat a Wounded Manatee - The New York Times - January 27th, 2021
- We tried The Body Shops new Drops of Youth skincare range heres what we thought - The Independent - January 27th, 2021
- Stem Cell Therapy Market to Witness Increase in Revenues by 2025 NeighborWebSJ - NeighborWebSJ - January 25th, 2021
- Here's Why The Body Shop Is A Cult Brand to Know Plus The Best-Sellers To Buy - GLAMOUR UK - January 23rd, 2021
- 4 Doctors Reveal the Pros and Cons to Microneedling Treatments - NewBeauty Magazine - January 23rd, 2021
- Ohio State establishing national standards for ALS genetic testing, research and patient care | Ohio State Medical Center - Wexner Medical Center -... - January 23rd, 2021
- Global Regenerative Medicine Market Insights, Overview, Analysis and Forecast 2022 NeighborWebSJ - NeighborWebSJ - January 23rd, 2021
- I Tried The Slugging Skincare Trend & Here's What Happened - GLAMOUR UK - January 22nd, 2021
- Industrial Nitrogen Market to Reach Value of USD 29.36 Billion by 2027 | Global Analysis, Statistics, Revenue, Demand and Trend Analysis Research... - January 22nd, 2021
- Research finds new proof about the systems controlling skin repair and regeneration - Microbioz India - January 19th, 2021
- Comprehensive analysis of cell therapy on chronic skin wound healing: a meta-analysis - DocWire News - January 19th, 2021
- COVID self-care tips for skin, hair and overall wellness - Los Angeles Times - January 19th, 2021
- Tess Daly opens up about being "grateful" for her body and not dwelling on the negatives - Allaboutyou - January 19th, 2021
- Eye stem cell transplant to treat blindness bolsters retinal function in monkeys - FierceBiotech - January 14th, 2021
- Seattle researchers find clues for treatments that could eliminate HIV in infected patients - GeekWire - January 14th, 2021
- Reversing The Aging Clock With Epigenetic Reprogramming - Bio-IT World - January 14th, 2021
- Bath And Body Routines That Make You Look And Feel Good From Day To Night - Forbes - January 12th, 2021
- Worldwide Organ and Tissue Transplantation and Alternatives Industry to 2024 - Featuring Mylan, Novartis & Pfizer Among Others -... - January 12th, 2021
- BENEV Announces Investigative Report on Combination Treatment with Human Adipose Tissue Stem Cell- derived Exosomes and Fractional CO2 Laser for Acne... - January 9th, 2021
- Factor Bioscience spins out a new cell therapy player with eyes on the clinic within 2 years - Endpoints News - January 9th, 2021
- Spinogenix Wins Grant to Advance Testing of Potential Oral Therapy - ALS News Today - January 9th, 2021
- Ulta Beautys Love Your Skin Event Is Here | January 2021 - Allure - January 9th, 2021
- Exosome Therapeutic Market Overview By Size, Share, Trends, Growth Factors and Leading Players With Detailed Analysis of Industry Structure - KSU |... - January 9th, 2021
- Global Organ and Tissue Transplantation and Alternatives Market to 2024 - Impact Analysis of COVID-19 - Yahoo Finance - January 9th, 2021
- A celebrity dermat's tips for new moms on how to deal with postpartum hair and skin issues - VOGUE India - January 9th, 2021
- FOREO UFO 2 Review: Is It Worth The Hype? - GLAMOUR UK - January 9th, 2021
- The Amniotic Fluid Stem Cell Therapy Market to be synonymous to vertical growth between 2018 and 2026 - LionLowdown - January 5th, 2021
- 2021: What are the best self-care products to buy in the new year? - The Jerusalem Post - January 3rd, 2021
- The Complete Guide to Laser Treatments for Hair and Skin | The Science of Beauty Podcast | Allure - Allure - December 30th, 2020
- The big scientific breakthroughs of 2020 - The Week - December 30th, 2020
- Nociceptive neurons shown to boost hematopoiesis | 2020-12-28 - BioWorld Online - December 28th, 2020
- Getting to the root of why hair goes gray - messenger-inquirer - December 26th, 2020
- What causes chafing rash? Remedies, treatment, and prevention - Medical News Today - December 24th, 2020
- Rash on black skin: Pictures, symptoms, and treatments - Medical News Today - December 24th, 2020
- Everything You've Ever Wanted to Know About Body Hair - Allure - December 24th, 2020
- 2020 in Neuroscience, Longevity, and AIand What's to Come - Singularity Hub - December 22nd, 2020
- Hair loss, body odor, irregular periods: Covid-19 isolation does weird things to our bodies - Vox.com - December 22nd, 2020
- Scientists have restored youth to aging eyes in mice - Massive Science - December 21st, 2020
- The Adrenomyeloneuropathy Treatment Market to grow on an emphatic note from 2019 to 2029 - PharmiWeb.com - December 21st, 2020
- At 14.6% CAGR, Cell Banking Outsourcing Market 2020 Industry Analysis of Current Trends and Opportun - PharmiWeb.com - December 21st, 2020
- The Definitive Guide to All Things Vegan By Drunk Elephant - LIVEKINDLY - December 21st, 2020
- The facts about the danger of melanoma - The Hudson Reporter - December 17th, 2020
- A Tried And Tested Guide On How To Win The War Against Maskne - Forbes - December 13th, 2020
- COVID-19 and graft-versus-host disease: a tale of two diseases (and why age matters) - DocWire News - December 10th, 2020
- CBD: the beauty ingredient trend that can't be stopped - CosmeticsDesign.com USA - December 10th, 2020
- The Technology Behind Bone Marrow Cellular Processing: The PXP System - marketscreener.com - December 9th, 2020
- City of Hope Doctors Present Innovative Therapies to Better Treat Blood Cancers at American Society of Hematology Virtual Conference - BioSpace - December 9th, 2020
- How to Minimize Inflammation and Prevent Your Skin from Inflammaging - Coveteur - December 5th, 2020
- Reversing vision loss by turning back the aging clock - FierceBiotech - December 5th, 2020
- Clinical Trials Offer Opportunities to Change Practice to Improve Prevention and Treatment of Blood Disorders - PRNewswire - December 5th, 2020
- The Amniotic Fluid Stem Cell Therapy Market to Cascade the Success Trove - The Haitian-Caribbean News Network - December 2nd, 2020
- Global Anti-Ageing Drugs Industry Market Growth Graph To Demonstrate Inclination Towards Positive Axis By 2026 - The Courier - December 2nd, 2020
